APCER Life Sciences eyes growth in 2018

< back to all business news articles

17/01/2018

Leading clinical safety operator, APCER Life Sciences, aims to grow its global offering in 2018 and has secured funding support from Clydesdale Bank.

The London-based company, a member of the Hong Kong based APC Group, has subsidiaries in the US, India and Hong Kong, and specialises in outsourced pharmacovigilance (monitoring effects of medical drugs after they are licensed for use) and medical report writing services. It delivers a variety of services to clients, which include leading multi-national pharmaceutical companies.

Working closely with Clydesdale Bank, APCER has secured a funding package that includes term lending and invoice finance facilities. The funding package will support working capital, enable investment in people and infrastructure to enhance global delivery capabilities, and allow APCER to further its digital strategy.

Gopal Menon, APCER Director and APC Group Vice Chairman, said: “Our aim in the coming year is to enhance our technology, continue to grow and develop our global team, and to position ourselves to capitalise on the many opportunities in our sector.

“That objective will be assisted by the support provided by Clydesdale Bank, who have structured a facilities package to meet our specific requirements. It has been a very positive experience dealing with their team, who have demonstrated a real understanding of our sector and our business strategy.”

Mark Cook, Director, Specialist and Acquisition Finance at Clydesdale Bank, said: “We are delighted to have supported APCER Life Sciences with a flexible finance package that provides further investment into this successful, fast growing and innovative business. Clydesdale Bank funding will enable management to drive the business forward into the next stage of its development.